Suggested remit: To appraise the clinical and cost effectiveness of ranibizumab port delivery system within its marketing authorisation for treating wet age-related macular degeneration.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 3983
Provisional Schedule
- Committee meeting:
- 08 September 2026
- Expected publication:
- 11 November 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- Roche (port delivery platform with ranibizumab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Macular Society
- Professional groups
- Royal College of Ophthalmologists
- Royal College of Physicians
- Associated public health groups
- None
- Comparator companies
- Bayer (aflibercept) (Confidentiality agreement signed, participating)
- MDBiologics (aflibercept) (Confidentiality agreement signed, participating)
- ADVANZ Pharma (aflibercept) (Confidentiality agreement not signed, not participating)
- Celltrion Healthcare (aflibercept) (Confidentiality agreement not signed, not participating)
- Genus Pharmaceuticals (ranibizumab intravitreal injection formulation) (Confidentiality agreement not signed, not participating)
- Novartis (brolucizumab, ranibizumab intravitreal injection formulation) (Confidentiality agreement not signed, not participating)
- Orion Pharma (ranibizumab intravitreal injection formulation) (Confidentiality agreement not signed, not participating)
- Outlook Therapeutics (bevacizumab gamma) (Confidentiality agreement not signed, not participating)
- Roche (faricimab) (Confidentiality agreement not signed, not participating)
- Samsung Bioepis (ranibizumab intravitreal injection formulation) (Confidentiality agreement not signed, not participating)
- Sandoz (aflibercept) (Confidentiality agreement not signed, not participating)
- Teva UK (ranibizumab intravitreal injection formulation) (Confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 06 February 2026 | Invitation to participate |
| 10 December 2025 - 08 January 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 18 June 2025 | Awaiting development. Please note that the timelines for this appraisal are anticipated to begin in early February 2026 with submissions expected in mid-April 2026. |
| 26 December 2022 | Note added to the project documents |
| 14 September 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 01 July 2022 | Note added to the project documents |
| 31 May 2022 | Note added to the project documents |
| 31 May 2022 | Topic selection. The topic was discussed at the Topic Selection Oversight Panel (TSOP) in April 2022. The panel concluded that the topic was suitable for a Technology Appraisal. Following conversations with the company, the scheduling of the evaluation is to be confirmed and stakeholders will be updated in due course. |
| 26 January 2022 - 23 February 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 26 January 2022 | In progress. In progress |
| 26 January 2022 | In progress. . |
For further information on our processes and methods, please see our CHTE processes and methods manual